| Document |
Document Title |
|
WO/2023/172726A1 |
Pharmaceutical compositions of the invention comprise diazepines derivatives having a disease-modifying action in the treatment of diseases associated with biological effect that include disease state, and any disease type/class involvin...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143389A1 |
The present disclosure relates to a fused heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, the present disclosure relates to a fused heterocyclic compound represented by general formu...
|
|
WO/2023/133089A1 |
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions ther...
|
|
WO/2023/125184A1 |
Provided are a tertiary amine lipid compound with a structure represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, and use thereof. The compound can damage a cell membrane or a lysosome membrane with ...
|
|
WO/2023/093787A1 |
A benzodiazepine compound having a structure represented by formula (I) and serving as a ROCK II kinase inhibitor, and an application thereof in a Rho kinase inhibitor drug and a preparation method therefor.
|
|
WO/2023/078369A1 |
The present invention relates to a compound as shown in formula (I). The present invention also provides a composition and preparation containing the compound, and a method for using and preparing the compound.
|
|
WO/2023/063722A1 |
The present invention relates to: a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof; a method for preparing the compound; and a pharmaceutical composition for preventing or treating diabetic perip...
|
|
WO/2023/057415A1 |
The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions in...
|
|
WO/2023/043040A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
|
WO/2023/037237A1 |
A process is described for preparing 3-[(4S)-8-bromo-l-methyl-6-(2-pyridinyl)-4H-imidazo [ 1,2-a] [ 1,4]benzodiazepine-4-yl]propionic acid methyl ester of formula (B) which comprises reacting methyl 3-((3S)-7-bromo-2-(2-hydroxy-propylami...
|
|
WO/2023/030295A1 |
A compound having a USP1 inhibitory activity or function and a pharmaceutically acceptable salt thereof. The compound has the structure of formula (I), and have substituents and structural features described in the present invention. Als...
|
|
WO/2023/020416A1 |
A tricyclic compound of formula (I), a pharmaceutical composition comprising same, and use thereof as an HDAC6 inhibitor.
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/241095A1 |
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof in combination with a composition comprising one or more B-cell leukemia/lymphom...
|
|
WO/2022/212538A1 |
The present disclosure relates to a class of diazepanone-fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also ...
|
|
WO/2022/189810A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2022/173627A2 |
Disclosed are methods, systems, components, and compositions for synthesis of sequence defined polymers. The methods, systems, components, and compositions may be utilized for incorporating novel substrates that include non-standard amin...
|
|
WO/2022/162693A1 |
The present invention relates to a class of benzodiazepine compounds and a process for preparation thereof. The 1,5-benzodiazepine compounds effectively 5 function on targeted enzymes such as tyrosine kinase and dihydrofolate reductase (...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2015/136557A9 |
The present invention provides compounds of formula (I), compositions, uses thereof and methods for inhibiting proliferation or obliterating cancer stem cells which includes killing; and/or inducing apoptosis in cancer stem cells. Includ...
|
|
WO/2022/105542A1 |
Disclosed are a deuterated 1,4-benzodiazepine-2,5-dione compound and the use thereof. Provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The disclosed 1,4-benzodiazepine-2,5-dione active com...
|
|
WO/2022/099011A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is...
|
|
WO/2022/082305A1 |
The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the am...
|
|
WO/2022/086892A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2022/034616A1 |
Described herein is a method for treating and/or preventing a disease or disorder or condition associated with NETosis, the method comprising: administering to a subject a compound as disclosed herein, or its polymorph, stereoisomer, pro...
|
|
WO/2022/022846A1 |
The present invention relates to a compound of general formula (I) wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula (I) binds to VDAC1 and is suitable for use in a method for treating diabetes or pre- diabetes ...
|
|
WO/2022/000443A1 |
Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
|
|
WO/2021/249463A1 |
The present invention relates to a compound as represented by formula (I). Also provided are a composition and a preparation containing the compound, and a method for using and preparing the compound.
|
|
WO/2021/237111A1 |
Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.
|
|
WO/2021/237112A1 |
Disclosed herein, inter alia, are compounds for inhibiting Notch and uses thereof.
|
|
WO/2021/226629A1 |
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses o...
|
|
WO/2021/218863A1 |
The present invention relates to the field of chemical medicine, and in particular, to a 1,5-dihydro-2,4-benzodiazepine-3-one derivative and an application thereof. The 1,5-dihydro-2,4-benzodiazepine-3-one derivative provided by the pres...
|
|
WO/2021/208945A1 |
Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable sal...
|
|
WO/2021/208918A1 |
Provided are a class of compounds, represented by formula (I"'), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds ...
|
|
WO/2021/188620A1 |
Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sa...
|
|
WO/2021/169963A1 |
Provided are a compound containing an aromatic group as well as a stereoisomer, a tautomer or a pharmaceutically acceptable salt of the compound. Further provided is a method related to preparation and use of the compound. A pharmaceutic...
|
|
WO/2021/170913A1 |
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...
|
|
WO/2021/163676A1 |
The present invention provides methods of preparing compound of Formula (I), wherein the compounds are represented by the structure of Formula (I) wherein: R1 each is independently F, Cl, Br, I, OCH3, CN or NO2; R2 each is independently ...
|
|
WO/2021/141969A1 |
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...
|
|
WO/2021/018298A1 |
Disclosed is a class of indolo-seven-membered acyloxime compounds, and specifically disclosed are compounds as shown in formula (I), and pharmaceutically acceptable salts thereof.
|
|
WO/2020/245213A1 |
The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising ...
|
|
WO/2020/242923A1 |
This disclosure relates to uses of radiation and benzodiazepines optionally in combination with other anticancer agents for treating cancer. In certain embodiments, this disclosure relates to methods of using radiation, benzodiazepines, ...
|
|
WO/2020/210662A1 |
The present disclosure provides compounds of formula (I), as described herein, their pharmaceutically acceptable salts, and their pharmaceutical compositions, which are effective in reducing the expression level of KLF5 or EGR1 in a livi...
|
|
WO/2020/200283A1 |
In an embodiment of the present invention, a fluorenone ligand compound for an α7 nicotinic acetylcholine receptor represented by the following formula (I) is provided, wherein, X is a 6- to 10-membered nitrogen-containing heterocyclic ...
|
|
WO/2020/192637A1 |
Disclosed are a solid form and a crystal form of a compound represented by formula (1) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related disease...
|
|
WO/2020/184670A1 |
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...
|
|
WO/2020/131000A1 |
The invention relates to a crystalline form of the Compound (I), wherein the crystalline form displays its strongest reflection, stated as a 2Θ value, at 25±0.2°, in an X-ray powder diffraction pattern. The invention also relates to a...
|
|
WO/2020/127390A1 |
A method is provided for preparing a compound d having the formula (D) The method comprises carrying out the following reaction (c) → (d), where the reaction is carried out at a temperature of at least 100 °C and in the presence of a ...
|
|
WO/2020/127385A1 |
A method is provided for preparing a compound d having the formula: Formula (I). The method comprises carrying out the following reaction: Formula (i), (ii), (d) where: step (i) is carried out in the presence of a metal catalyst and a hy...
|
